Table 2. Characteristics of subjects enrolled in the phase 1 study of dose-escalated doxorubicin in cycles 1–3 ABVD.

	Dose level of doxorubicin
	35 mg m–2	45 mg m–2	55 mg m–2
Number	6	12	6
Age
Median	42.5	37	30.5
Range	21–56	18–57	24–45
Gender
Male	2	6	4
Female	4	6	2
Stage	IIxA–IVxB	IIAa–IVxB	IIIB–IVB
Hasenclever score
Median	1	2	3
Range	0–3	0–6	0–4

Abbreviation: ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine.

^aUnsuitable for XRT, x signifies bulk disease.